1. Background {#sec1}
=============

Alzheimer\'s disease (AD) is currently conceptualized as a clinicobiological entity [@bib1], [@bib2], [@bib3]. Accordingly, modern clinical and research criteria have integrated biomarkers for the *in-vivo* identification of the AD pathophysiological state [@bib4], [@bib5], [@bib6], [@bib7]. Biomarkers can be divided into two main modalities: neuroimaging and cerebrospinal fluid (CSF) biomarkers and can also be subdivided according to their specificity for different pathophysiological categories including: cerebral amyloid deposition, tau pathology, and neurodegeneration [@bib8].

Current diagnostic recommendations consider the information provided by a growing number of biomarkers. Consequently, biomarker-based classification systems have been proposed to integrate the information provided by the different sets of biomarkers. Specifically, the A/T/N system has been recently proposed to dichotomize the biomarker results from three different pathophysiological categories (cerebral amyloid deposition \[A\], tau pathology \[T\], and neurodegeneration \[N\]). While some classification systems consider the individual clinical status [@bib4], [@bib5], [@bib7], [@bib9], others such as the A/T/N system are proposed to be applicable across all clinical diagnostic stages independent of cognitive status [@bib10]. This approach provides an integrative framework for AD research and cognitive aging.

However, the operationalization of biomarker-based classification systems poses challenges before it can be applied in clinical practice. Foremost, subject classification at the individual level must be consistent across biomarker modalities and be faithful to the pathophysiology. Hence, the consistency of biomarker-based classification systems will essentially rely on a good agreement between biomarkers belonging to the same pathophysiological category. Nonetheless, we have previously shown in a study in mild cognitive impairment (MCI) that the selection of biomarkers may be determinant for the individual subject classification [@bib11].

Despite significant previous efforts [@bib12], [@bib13], [@bib14], a systematic appraisal of the agreement between the biomarkers related to each of the pathophysiological categories of the A/T/N system had not been conducted. In this study, we used the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) multimodal biomarker data to evaluate for the first time: (i) the consistency of available biomarkers for subject classification within the A/T/N system; and (ii) the agreement and correlation across these biomarkers along the AD continuum.

2. Methods {#sec2}
==========

2.1. Study population {#sec2.1}
---------------------

Data used in the preparation of this article were obtained from the ADNI database ([adni.loni.usc.edu](http://adni.loni.usc.edu){#intref0010b}). The ADNI was launched in 2003 as a public-private partnership, led by a principal investigator Michael W. Weiner, MD. The primary goal of the ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of MCI and early AD. For the present study, we selected 711 individuals from ADNI-2 (n = 595) and ADNI-GO (n = 116) with available CSF results, 3T MRI study, and \[18F\] florbetapir (FBP) PET imaging at baseline. ADNI-1 subjects were excluded due to the lack of 3T MRI. For up-to-date information, see [www.adni-info.org](http://www.adni-info.org){#intref0015}.

2.2. CSF analyses {#sec2.2}
-----------------

We obtained the baseline CSF amyloid β (Aβ) 1--42, total tau (t-tau), and phosphorylated tau (p-tau) levels from the ADNI database. We applied the validated ADNI thresholds for subject dichotomization (Aβ 1--42: 192 pg/mL; t-tau: 93 pg/mL; and p-tau: 23 pg/mL) [@bib15].

2.3. Magnetic resonance imaging {#sec2.3}
-------------------------------

### 2.3.1. MRI acquisition and processing {#sec2.3.1}

The details of acquisition are available elsewhere (<http://www.adni-info.org>). Cortical reconstruction of the T1 images was performed with FreeSurfer (version 5.1; <http://surfer.nmr.mgh.harvard.edu>), as previously described [@bib16], [@bib17], [@bib18], [@bib19]. From 711 MRI studies, 151 were excluded because of segmentation errors.

### 2.3.2. Adjusted hippocampal volumes {#sec2.3.2}

Adjusted hippocampal volume values were directly downloaded from the ADNI database. We applied the previously validated threshold for adjusted hippocampal volume (−0.63) for subject dichotomization [@bib20].

### 2.3.3. Cortical signature of Alzheimer\'s disease {#sec2.3.3}

In this work, we applied a previously validated cortical signature of Alzheimer\'s disease [@bib21] to extract the individual mean cortical thickness [@bib21], [@bib22]. We calculated the cutoff with the highest Youden\'s index (cutoff = 2.53; area under the receiver operating characteristic curve = 0.90) to differentiate FBP-positive AD dementia patients (n = 114) from FBP-negative healthy controls (HCs; n = 108). This cutoff was applied for subject dichotomization.

2.4. Positron emission tomography {#sec2.4}
---------------------------------

The details of acquisition for \[18F\] FBP PET and \[18F\] fluorodeoxyglucose PET (FDG PET) are available elsewhere (<http://www.adni-info.org>). We downloaded the Landau\'s composite standardized uptake value ratio both for FBP PET and FDG PET from the ADNI database. We then applied the validated thresholds for FBP PET (1.11) [@bib23] and FDG PET (1.2) [@bib24] for subject dichotomization.

2.5. Definition of the AD state and stages in the AD continuum {#sec2.5}
--------------------------------------------------------------

In this study, we differentiate between the clinical group and AD stage. We refer to the clinical groups, (a) HCs, (b) MCI patients, and (c) dementia patients, when we include all subjects irrespective of the biomarker status. We define the AD state by the presence of a positive amyloid PET according to the International Working Group-II criteria [@bib6]. Based on the FBP PET positivity, we classified HC, MCI, and demented participants into asymptomatic at risk for AD, prodromal AD, and AD dementia, which define the different stages of the AD continuum.

2.6. Statistical methods {#sec2.6}
------------------------

Continuous variables are described as mean and standard deviation, and categorical variables are described as percentages. Differences in baseline characteristics between groups were assessed using the t-test for continuous variables and the Chi-square for dichotomous or categorical data. Nonparametric tests were applied when variables did not follow a normal distribution. We calculated the Spearman correlation coefficient (for raw values) and the Cohen\'s Kappa index (for dichotomous classification) to test agreement between biomarkers. The kappa index provides a reliable measure of chance-corrected classification between different measures. We also explored if threshold adjustment could have the potential to improve the agreement. For this purpose, for each biomarker pair, we calculated the agreement using all possible values in one biomarker while keeping the cutoff of the other biomarker fixed at the validated threshold.

The agreement was examined in (a) the whole cohort and (b) all clinical groups (HC, MCI, and dementia patients). The correlations were examined in (a) the whole cohort, (b) all clinical groups (HC, MCI, and dementia patients), and (c) the AD continuum (AD state; with asymptomatic at risk for AD, prodromal and AD dementia stages) to assess stage-dependent relationships and because pooling together different populations (with and without an AD pathophysiological process; AD state) may generate spurious correlations.

We applied a previously proposed grading for the correlation coefficients and kappa indexes [@bib25], [@bib26]. We labeled kappa values below 0.6 as "inadequate" as suggested for studies in medical sciences [@bib25]. Statistical significance for all tests was set at 5% (α = 0.05), and all statistical tests were two-sided. All analyses were performed using SPSS 20.0 (Armonk, NY: IBM Corp.).

3. Results {#sec3}
==========

3.1. Demographics and patients\' characteristics {#sec3.1}
------------------------------------------------

[Table 1](#tbl1){ref-type="table"} shows the demographic, cognitive, and genetic data of the participants for each clinical group (cognitively healthy, MCI, and dementia) and in the subgroup of participants within the AD continuum (asymptomatic at risk for AD, prodromal AD, and AD dementia stages). A total of 711 subjects were included (mean age 72.5 years, 54.3% women). The MCI group was the largest group (n = 423, 59.5%) whereas the AD dementia group was the smallest one (n = 129, 18.1%). The MCI group was younger than the AD dementia and control group. As expected, the Mini-Mental State Examination frequency was lower and the apolipoprotein E (*APOE* ε4) frequency higher in the MCI and dementia groups when compared with the cognitively HCs. Within the AD continuum (as defined by a positive FBP PET), the group of prodromal AD was the largest group (n = 232, 58.4%), whereas the asymptomatic at risk for AD group was the smallest one (n = 51, 12.8%). The prodromal AD group was slightly younger than the asymptomatic at risk for AD group. The *APOE* ε4 frequency was higher in the prodromal and dementia AD groups when compared with the asymptomatic at risk for AD group.Table 1Demographic, clinical, and cognitive data along clinical groups and the AD continuumHealthy controlsMCIDementiaAll participantsWhole sample n, (% of total sample)159 (22.4)423 (59.5)129 (18.1)711 (100) Age, years73.5 ± 6.3^b^71.5 ± 7.3^ac^74.4 ± 8.4^b^72.5 ± 7.4 Women, n (%)78 (49.1)231 (54.3)77 (59.7)386 (54.3) Education, years16.6 ± 2.5^c^16.2 ± 2.615.7 ± 2.6^a^16.2 ± 2.6 *APOE* ε4, n (%)43 (27)^bc^202 (47.8)^ac^86 (66.7)^ab^331 (46.6) MMSE29.1 ± 1.1^bc^28.1 ± 1.7^ac^23.2 ± 2^ab^27.4 ± 2.6 ADAS-Cog9.1 ± 4.5^bc^14.8 ± 7^ac^28 ± 11^ab^16.3 ± 10.1Asymptomatic at risk for ADProdromal ADAD dementiaAll AD stagesAD continuum[∗](#tbl1fnlowast){ref-type="table-fn"} n, (% of AD continuum[∗](#tbl1fnlowast){ref-type="table-fn"})51 (12.8)232 (58.4)114 (28.7)397 (100) Age, years75.7 ± 5.8^b^72.8 ± 6.7^a^74 ± 8.473.6 ± 7.1 Women, n (%)19 (37.3)128 (55.2)63 (55.3)210 (52.9) Education, years16 ± 2.416 ± 2.815.6 ± 2.715.9 ± 2.7 *APOE* ε4, n (%)21 (41.2)^bc^155 (66.8)^a^85 (74.6)^a^261 (65.7) MMSE29.1 ± 0.9^bc^27.7 ± 1.8^ac^23.1 ± 2.1^ab^26.6 ± 2.9 ADAS-Cog10 ± 4.6^bc^17.1 ± 6.9^ac^30.2 ± 11.4^ab^20 ± 10.7[^2][^3]

3.2. Consistency of biomarker combinations across A/T/N categories at the individual level {#sec3.2}
------------------------------------------------------------------------------------------

In the whole sample, the percentage of subjects inconsistently classified by the biomarkers in the A/T/N system varied from 12.2% to 44.5%. For illustrative purposes, [Fig. 1](#fig1){ref-type="fig"}A shows the proportion of subjects classified in a different category when taking as the reference the classification using CSF core AD biomarkers. In the whole sample, the percent of misclassification varied from 12.5% to 34.3% when only one biomarker was replaced, to 39.6%--44.5% when two of the three biomarkers where modified. As shown in [Fig. 1](#fig1){ref-type="fig"}B--D, similar results were observed when restricting the analyses to the cognitively healthy, MCI, and dementia groups, respectively.Fig. 1Percent of A/T/N misclassifications for the different biomarker combinations in (A) the whole sample, (B) cognitively healthy controls, (C) mild cognitive impairment and (D) dementia subjects. The percent of participants classified in different categories are shown for each biomarker combination when compared with classification with Aβ 1--42, p-tau, and t-tau. Percent of misclassifications are shown in green when one biomarker was changed, and in orange, when two biomarkers were changed. Abbreviations: Aβ, amyloid β; ADsig, Alzheimer's disease cortical signature; aHV, adjusted hippocampal volume; FBP PET, \[18F\] florbetapir positron emission tomography; FDG PET, \[18F\] fluorodeoxyglucose positron emission tomography; p-tau, phosphorylated tau; t-tau, total tau.

3.3. Agreement and correlation between amyloid biomarkers {#sec3.3}
---------------------------------------------------------

[Fig. 2](#fig2){ref-type="fig"} shows the agreement and correlation between CSF Aβ1--42 and FBP PET in the whole sample and in the different clinical groups. The agreement was moderate to high in the whole sample (k = 0.74, *P* \< .001) and in all clinical groups (k = 0.58, k = 0.75, and k = 0.78, all *P* \< .05; for HC, MCI, and dementia patients, respectively).Fig. 2Agreement and correlation between amyloid biomarkers across the AD continuum. Agreement and correlation between CSF Aβ1--42 and FBP PET in (A) the whole sample, (B) cognitively healthy controls, (C) mild cognitive impairment and (D) dementia subjects. Correlations were calculated for each of these groups and for the subgroups with both positive CSF Aβ1--42 and FBP PET (red dots) as well as those with both negative CSF Aβ1--42 and FBP PET (green dots). Abbreviations: Aβ, amyloid β; CSF, cerebrospinal fluid; FBP PET, \[18F\] florbetapir positron emission tomography.

The correlations changed in the different clinical groups. It was moderate to high for the whole sample (Rho = −0.73, *P* \< .001), HC (Rho = −0.6, *P* \< .001), and MCI (Rho = −0.74, *P* \< .001), but it was negligible in the dementia group (Rho = −0.24, *P* = .007).

We then restricted the analysis to the subgroup of patients with a positive FBP PET. In this subgroup, the correlation between CSF Aβ1--42 and FBP PET was low (Rho = −0.30, *P* \< .001). However, we found a decreasing magnitude of correlation between both measures along the AD continuum from asymptomatic at risk for AD (Rho = −0.48, *P* \< .001) to prodromal AD (Rho = −0.31, *P* \< .001) and no significant correlation in the AD dementia group ([Fig. 3](#fig3){ref-type="fig"}A). Of note, when we subdivided the patients with prodromal AD into early MCI and late MCI, we also found the same pattern, a weak correlation in early MCI (n = 125; Rho = −0.43, *P* \< .001) and no correlation in late MCI (n = 107; Rho = −0.10, *P* = .29). As seen in [Fig. 2](#fig2){ref-type="fig"}, we obtained essentially the same results when the AD state was defined by the positivity of both amyloid biomarkers.Fig. 3Absolute correlation coefficient within and across amyloid, tau and neurodegeneration biomarkers along the AD continuum. (A) Significant correlations\* between biomarkers in different pathophysiological categories along the AD clinical continuum; (B) Significant correlations\* between biomarkers in the same pathophysiological category along the AD clinical continuum; \*: a relevant correlation was defined by a correlation coefficient \>0.3 in at least one clinical category of the AD continuum. The 0.3 threshold is marked with a red-dotted line. Abbreviations: AD, Alzheimer's disease; Aβ, amyloid β; FDG, \[18F\] fluorodeoxyglucose; FBP, \[18F\] florbetapir.Fig. 4Agreement between neurodegeneration biomarkers. Dynamic agreement between neurodegeneration biomarkers with cutoff modification. For each biomarker pair, we calculated the agreement using all possible values in one biomarker while keeping the cutoff of the other fixed. Abbreviations: CSF, cerebrospinal fluid; AD sig, Alzheimer's disease cortical signature; FDG PET, \[18F\] fluorodeoxyglucose positron emission tomography; HVa, adjusted hippocampal volume.Fig. 5Potential agreement between CSF tau biomarkers. (A) Correlation and agreement between CSF t-tau and p-tau according to the previously validated p-tau threshold and with a calculated threshold for an optimal agreement; (B) dynamic agreement of t-tau and p-tau with threshold modification. Abbreviation: CSF, cerebrospinal fluid.

3.4. Agreement and correlation between neurodegeneration biomarkers {#sec3.4}
-------------------------------------------------------------------

[Table 2](#tbl2){ref-type="table"} shows the agreement and correlation between amyloid, tau, and neurodegeneration biomarkers in the whole sample. The agreement between neurodegeneration biomarkers did not reach adequate agreement (k \> 0.6), neither in the whole sample nor in different clinical groups. In the whole sample, the highest agreement was found between the adjusted hippocampal volume (aHV) and the MRI cortical signature (k = 0.44, *P* \< .05). When we restricted the analysis to subjects within the AD continuum, we observed similar results ([Table 2](#tbl2){ref-type="table"}).Table 2Correlation and agreement across biomarkers in the whole sample and in the whole sample and in subjects within the AD continuum (positive FBP PET)Aβ1--42FBP PETt-Taup-TauMRI aHVMRI ADsigFDG PETAβ1--42**−0.73\***−0.48\*−**0.52\***0.42\*0.38\*0.42\*−0.30\*−0.20\*−0.22\*0.25\*0.25\*0.26\*FBP PET**0.74\*0.58\*0.59\***−0.39\*−0.38\*−0.39\*-0.33\*0.32\*−0.25\*−0.27\*−0.29\*t-Tau0.37\*0.44\***0.76\***−0.36\*−0.38\*−0.39\*0.09\*-**0.66\***−0.20\*−0.29\*−0.29\*p-Tau0.33\*0.37\*0.29\*−0.29\*−0.35\*−0.36\*0.32\*-0.18\*−0.13\*−0.24\*−0.25\*MRI aHV0.30\*0.34\*0.28\*0.15^ns^**0.55\***0.48\*0.10\*-0.10^ns^0.03^ns^**0.52\***0.45\*MRI ADsig0.26\*0.30\*0.31\*0.15\*0.44\*0.49\*0.08\*-0.17\*0.07\*0.36\***0.55\***FDG PET0.29\*0.30\*0.37\*0.13\*0.38\*0.43\*0.07\*-0.26\*0.07\*0.32\*0.40\*[^4][^5][^6]

The correlation within neurodegeneration biomarkers in the whole sample ranged from moderate (Rho = 0.55, *P* \< .05, for AD cortical signature and the aHV) to low (Rho = −0.36, *P* \< .05, for the aHV and t-tau). We then assessed the correlations between neurodegeneration biomarkers in each clinical group. In HC, no significant correlations were found within the neurodegeneration biomarkers. In MCI patients, aHV was correlated with both cortical thinning within the AD MRI cortical signature and the FDG PET hypometabolism (Rho = 0.52, *P* \< .001 and Rho = 0.37, *P* \< .05, respectively) and the FDG PET also correlated with the cortical AD signature (and Rho = 0.42, *P* \< .05). In dementia patients, the correlations were lost, and only the AD cortical signature and FDG PET showed a correlation with each other (Rho = 0.40, *P* \< .05).

We then analyzed the correlations in the AD continuum. Importantly, all correlations between neurodegeneration biomarkers decreased when we restricted the analysis to the subjects within the AD continuum, except for the correlation between the cortical AD signature and the FDG PET ([Fig. 3](#fig3){ref-type="fig"}A).

CSF p-tau was the sole tau pathology biomarker included in this study due to the small number of patients with tau PET data available in ADNI-2 and ADNI-go cohorts.

We next explored if threshold adjustment could have the potential to improve the agreement. For this purpose, for each neurodegeneration biomarker pair, we calculated the agreement using all possible values in one biomarker while keeping the cutoff of the other biomarker fixed. Importantly, the agreement between neurodegeneration biomarkers did not improve with threshold adjustment as shown in [Fig. 4](#fig4){ref-type="fig"}.

3.5. Agreement and correlation between biomarkers of different pathophysiological categories {#sec3.5}
--------------------------------------------------------------------------------------------

The agreement between biomarkers of different pathophysiological categories did not reach adequate agreement (k \> 0.6) neither in the whole sample nor in the different clinical groups or along the AD continuum.

In the whole sample, biomarkers of different pathophysiological categories showed varying degrees of correlation from negligible (Rho = - 0.29, *P* \< .05, for aHV and p-tau) to moderate (Rho = 0.59, *P* \< .001, for p-tau and FBP PET).

t-Tau and p-tau showed the highest correlation in the whole sample (Rho = 0.76, *P* \< .001), in all the clinical groups (Rho = 0.62--0.77, all *P* \< .001) and along the AD continuum (Rho = 0.75--0.59, all *P* \< .001). As shown in [Fig. 5](#fig5){ref-type="fig"}A, this high correlation contrasted with their low agreement (k = 0.29, *P* \< .05). Importantly, as shown in [Fig. 5](#fig5){ref-type="fig"}B, the modification of the thresholds for either p-tau cutoff (from 23 to 39 pg/mL) or t-tau (from 93 to 56 pg/mL) greatly improved the agreement between t-tau and p-tau (k = 0.56 and k = 0.59, for the resulting p-tau and t-tau adjusted threshold, respectively).

We then looked at correlations between other biomarkers from different pathophysiological categories in the AD continuum ([Fig. 3](#fig3){ref-type="fig"}B). In the preclinical phase, FBP PET, t-tau, and p-tau were the only biomarkers that showed relevant correlations (Rho \> 0.3). In prodromal AD, multiple biomarkers from different modalities were correlated with each other. All correlations were lost in the dementia stage with the sole exception of the correlation between t-tau and p-tau.

4. Discussion {#sec4}
=============

This article makes several novel contributions. First, to the best of our knowledge, our article is the first to assess the consistency and reproducibility of the A/T/N classification system and gives a clear vision of the limitations of its empirical application (i.e., lack of reproducibility). The observed inconsistencies in the individual subject classification were derived from insufficient agreement between biomarkers within the different pathophysiological categories. Second, this is the first article to prove that the agreement between biomarkers related to the same pathophysiological category cannot be improved with the modification of biomarker cutoffs. Third, we highlight the existence of dynamic correlations between biomarkers along the AD continuum (i.e., different correlations in the different stages of the AD continuum). Finally, we show that the agreement between p-tau and t-tau could be significantly improved by means of cutoff modification.

We found inconsistent individual subject classification when using different biomarker combinations in up to 44.5% of the participants. This result shows a limitation associated with the A/T/N classification system, in which biomarkers of different modalities are considered interchangeable. These systems, which are based on the successive dichotomization of biomarkers related to different pathophysiological categories are very sensitive to the lack of agreement between biomarkers ascribed to the same pathophysiological process. Therefore, while the addition of new categories to the classification systems theoretically refines the classifications, this additional complexity, in the absence of high agreement between biomarkers within each category, decreases the consistency of classifications. Thus, a balance between precision (i.e., number of pathophysiological categories) and reproducibility must be found to ensure the generalization of the results.

Amyloid biomarkers showed the highest agreement in the whole sample and in all clinical groups, but it never exceeded a kappa of 0.8. The correlation between CSF Aβ1--42 and FBP PET values was very variable. It was good in the whole sample, in HC and MCI patients, but negligible in dementia patients. Importantly, the correlation between both measures decreased from asymptomatic at risk for AD to prodromal AD and was not significant in the AD dementia group. Both CSF Aβ1--42 and amyloid PET have been reported to correlate with fibrillar amyloid deposition [@bib27], [@bib28], and early studies already emphasized the high agreement and strong correlations between the two [@bib28], [@bib29], [@bib30]. However, despite efforts that attempted to convert CSF Aβ1--42 and amyloid PET values [@bib31], recent studies have suggested a nonlinear correlation between these two biomarkers [@bib32]. We did replicate the good agreement between both amyloid measures, but we expand previous findings by showing that the strong correlations found when merging amyloid-positive and amyloid-negative populations together may be, at least in part, spurious. In the AD continuum, CSF Aβ1--42 and amyloid PET values only modestly correlate in the preclinical and early prodromal AD stages. Taken together, these results confirm the utility of both CSF Aβ 1--42 and FBP PET as state biomarkers but also reinforce the notion that amyloid biomarkers are not fully interchangeable to quantify the amyloid cerebral burden at the different stages of the disease [@bib33].

Neurodegeneration biomarkers showed inadequate agreement and were poorly correlated. Modest correlations between neurodegeneration biomarkers have been reported in previous studies [@bib34], as recognized in the recently proposed A/T/N classification system [@bib10]. A number of previous studies have assessed the relationship between neuroimaging biomarkers. However, these studies were restricted to a particular clinical stage, and they did not assess the effect of substituting biomarkers within a given category on individual subject classification consistency [@bib35], [@bib36]. Conversely, we found dynamic relationships between neurodegeneration biomarkers along the AD continuum. There were no correlations in the preclinical stage, a stage in which little neurodegeneration is expected to occur, were maximal in the prodromal AD stage, when significant neurodegeneration accumulates, and were lost in the AD dementia stage, when the neurodegenerative load is maximal. The heterogeneity of neurodegenerative changes in the preclinical stage of AD has been underscored in the recently proposed criteria, where "downstream topographical biomarkers" are not considered suitable for the definition of the preclinical stage of AD [@bib7]. These results suggest that neurodegeneration biomarkers are not interchangeable to track neurodegeneration.

In addition, some important observations regarding neurodegeneration biomarkers should be highlighted. First, CSF t-tau did not correlate with the rest of neurodegeneration biomarkers. Some recent findings may help in the interpretation of this observation. While neuroimaging biomarkers may be informative regarding the cumulative neurodegenerative load (i.e., cortical thickness and metabolism decreases with disease progression), recent longitudinal studies suggest that CSF tau biomarkers may not increase over time, thus limiting their ability to track neurodegeneration over disease course [@bib37], [@bib38]. Second, our two MRI-derived biomarkers where only moderately correlated and showed a moderate agreement in the AD continuum. Of note, the AD cortical signature and the FDG PET showed the highest correlation in the AD continuum and were the two only biomarkers correlated in the AD dementia stage. This finding underlines the importance of considering the topography of the neurodegeneration. Both MRI and FDG PET AD cortical signatures track cortical changes as opposed to the aHV, which is a reflection of medial temporal lobe atrophy [@bib39]. Network-based diagnosis is currently being developed [@bib40], based on the evidence that large-scale networks are key to understand regional vulnerability in neurodegenerative disorders and to understand clinical heterogeneity [@bib41]. Future classification systems should consider the information contained at the network level.

The definition of cutoffs for continuous biomarker measures is crucial both for the development of consistent classification systems and for the reproducibility of findings across cohorts [@bib11], and significant efforts have been made in this regard, analyzing different methods for defining biomarker positivity [@bib42]. Although we only used one previously validated threshold for positivity, we run several simulations calculating different thresholds that would maximize the agreement between each biomarker combination. By doing that, only the agreement between CSF t-tau and CSF p-tau was relevantly improved. This finding suggests that the studied biomarkers related to the same pathophysiological process will not reach adequate agreement regardless on the method used to define positivity and therefore should not be equated [@bib10].

The relationship between CSF t-tau and CSF p-tau deserves further comment. These two biomarkers are ascribed to different pathophysiological categories in the A/T/N classification system based on the assumption that high p-tau levels are specific of the AD process whereas high t-tau levels are nonspecific [@bib10]. However, we showed that a good agreement could be achieved between these two measures with a modification of the cutoffs and that these biomarkers showed the highest correlation among all biomarkers in the AD continuum. A high correlation between CSF t-tau and p-tau levels has been previously reported in large meta-analysis across different platforms [@bib43], [@bib44], [@bib45]. Furthermore, previous large pathology-proven cohorts have reported similar correlations between the two CSF tau biomarkers and the neurofibrillary tangle load or tau PET [@bib46], [@bib47], [@bib48], [@bib49], [@bib50]. Further multimodal studies are needed to disentangle the relationship between tau PET and CSF tau biomarkers.

Our work also showed mild to moderate correlations between biomarkers of different pathophysiological categories. We found that FBP PET (but not CSF Aβ1--42) correlated with CSF t-tau and p-tau in the preclinical and prodromal AD stages. Previous studies showed a similar performance of FBP PET and the combination of CSF amyloid and tau and neurodegeneration biomarkers for the prediction of cognitive impairment [@bib51]. These results, together with the aforementioned relationship between t-tau and p-tau, stress that pathophysiological categories should be carefully delimited in the design of classification systems to ensure their ability to track nonoverlapping pathophysiological processes.

Our results have clinical implications as they are intended to impact the empirical application of biomarker-based classification systems [@bib52]. Researchers and clinicians should be cautious when interpreting multimodal biomarker profiles based on different biomarker combinations. If the robustness of multimodal biomarker profiling is not ensured, we might ascribe incorrect risks to a given individual, which has important implications both in clinical practice and clinical trials [@bib11]. Neurodegeneration biomarkers were the most problematic, especially when comparing neuroimaging and CSF biomarkers. As we have shown in [Fig. 4](#fig4){ref-type="fig"}, it is unlikely that a more precise cutoff definition will allow for the interchange of these biomarkers. However, neuroimaging and CSF biomarkers might provide complementary information. Neuroimaging studies might help in the differentiation of AD endophenotypes with appropriate neurodegenerative signatures accounting for disease heterogeneity [@bib39].

This study has several limitations. First, we could not assess the relationships within the tau pathology category because we only had one biomarker available in that category (p-tau) and tau PET was only available in a much smaller number of participants. However, a recent study showed low correlation and agreement between the two tau measures [@bib50]. Second, while we applied previously validated thresholds, these were derived from different approaches (i.e., pathological cohort as a gold standard or the best cutoff to differentiate HC from AD dementia patients). Third, we specifically calculated a cutoff for the AD signature as following previously published recommendations [@bib42]. Anyway, as previously discussed, the discordances between the studied biomarkers were independent of the cutoff with the exception of p-tau and t-tau.

In conclusion, we have shown that there are practical and theoretical problems in the A/T/N classification system that should be addressed to ensure its consistency, reproducibility, and accuracy.Research in Context1.Systematic review: The authors reviewed the literature using online databases looking for articles assessing the consistency of biomarker-based classification systems. Although previous studies had evaluated the agreement between biomarkers related to the same pathophysiological category, no previous studies have evaluated the consistency of the A/T/N system.2.Interpretation: The A/T/N system showed important inconsistencies when using different biomarker combinations. These inconsistencies where derived from insufficient agreement between biomarkers within the different pathophysiological categories. Moreover, stage-dependent relationships between biomarkers were found within the Alzheimer\'s disease continuum.3.Future directions: A balance between precision (i.e., number of pathophysiological categories) and reproducibility must be found to ensure the generalization of the results. Pathophysiological categories should be carefully delimited for the refinement of biomarker-based classification systems.
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[^1]: Data used in preparation of this article were obtained from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu){#intref0010}). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: <http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf>.

[^2]: NOTE. Results are mean ± standard deviation for continuous variables or frequency (%) for categorical variables. a: different from healthy controls/asymptomatic at risk for l AD (*P* \< .05); b: different from MCI/prodromal AD stage (*P* \< .05); c: different from dementia/AD dementia stage (*P* \< .05).

[^3]: The AD state was defined by a positive FBP PET; Alzheimer\'s Disease Assessment Scale-Cognitive Sub-scale, (ADAS-Cog); MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; CDR-SOB, Clinical Dementia Rating Sum of Boxes; *APOE*, apolipoprotein E.

[^4]: Abbreviations: ADsig, Alzheimer's disease signature; FBP PET, \[18F\] florbetapir positron emission tomography; FDG PET, \[18F\] fluorodeoxyglucose positron emission tomography; MRI, magnetic resonance imaging.

[^5]: NOTE. Spearman correlation coefficients are shown above the diagonal. Cohen\'s Kappa index for each pair of scores are shown below de diagonal; the first line in each box refers to the whole sample (n = 711), whereas the second line refers to the subset of subjects in the AD continuum (n = 397; positive FBP PET); \*, *P* \< .05; ns, non-significant.

[^6]: NOTE. In bold: correlation coefficients and Cohen\'s Kappa indexes with at least a moderate correlation (Rho \> 0.5) or a substantial agreement (k \> 0.6), respectively.
